Simon C Lowry
CIK 2044279 · View on SEC EDGAR ↗
First SEC filing: Nov. 21, 2024 · Latest: Nov. 21, 2024
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 6, 2025 | EBS | A | 62,500 | — | — | 91,982 Direct | +211.99% | Acquired | (price as of 2026-08-19) |
| March 6, 2025 | EBS | A | 62,500 | — | — | 102,999 Direct | +154.32% | Acquired | (price as of 2026-08-19) |
| Dec. 15, 2024 | EBS | A | 29,482 | — | — | 29,482 Direct | — | Acquired | (price as of 2026-08-19) |
| Dec. 15, 2024 | EBS | A | 40,499 | — | — | 40,499 Direct | — | Acquired | (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 6, 2025 | EBS | Employee Stock Options (Right to Buy) | Common Stock (62,500) | $5.80 | March 5, 2032 | 62,500 | Acquired |
| Dec. 15, 2024 | EBS | Employee Stock Option (Right to buy) | Common Stock (40,499) | $8.48 | Dec. 14, 2031 | 40,499 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Nov. 21, 2024 | EBS | Common Stock | 0 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
EBS
Chief Medical Officer and Head of Research and Development| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $545,002 | — | — | — | $289,668 | — | $10,500 | $1,471,276 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.